Compare ASAN & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASAN | ADMA |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2020 | 2012 |
| Metric | ASAN | ADMA |
|---|---|---|
| Price | $6.97 | $15.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 2 |
| Target Price | $12.62 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 5.6M | 3.2M |
| Earning Date | 06-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.13 | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $723,876,000.00 | $42,219,783.00 |
| Revenue This Year | $10.53 | $27.46 |
| Revenue Next Year | $9.03 | $21.11 |
| P/E Ratio | ★ N/A | $25.01 |
| Revenue Growth | 10.94 | ★ 43.85 |
| 52 Week Low | $6.51 | $13.76 |
| 52 Week High | $19.00 | $25.67 |
| Indicator | ASAN | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 38.61 |
| Support Level | $6.51 | $14.19 |
| Resistance Level | $8.20 | $16.28 |
| Average True Range (ATR) | 0.45 | 0.83 |
| MACD | 0.11 | -0.03 |
| Stochastic Oscillator | 23.01 | 17.62 |
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.